|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Indevus Pharmaceuticals: Premium Company Profile |
|
|
|
|
€ 396,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2007 |
Taille du document : |
58 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 86 pages | Août 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,pharmaceutical,pharmacovigilance
|
| Research
focus: |
industry structure,market size and estimates, |
| Geographic
focus: |
usa,united kingdom,india,germany,thailand,nigeria,... |
| |
|
|
|
|
| 127 pages | Mai 2003 | Anglais
|
|
|
| Main
focus: |
health expenditure,health insurance,...,hospitals,...
|
| Research
focus: |
market segmentation,demand analysis,market outlook, |
| Geographic
focus: |
australia,japan,usa,new zealand,france,canada,... |
| |
|
|
|
|
| 64 pages | Mars 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,atherosclerosis,hypertension
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,france,canada |
| |
|
|
|
|
| 64 pages | Novembre 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,dyslipidemia,pharmaceutical,...,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,france,canada,poland |
| |
|
|
|
|
| 70 pages | Septembre 2006 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,pharmaceutical,...
|
| Research
focus: |
market size and estimates,industry structure, |
| Geographic
focus: |
india,usa,china,france,united kingdom,malaysia,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Chinese Markets for Pharmaceuticals 225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic |
3 500,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis 188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
|
1 200,00 €
|
| |
| |
Antisense Therapy: Technical Aspects and Commercial Opportunities 334 pages | Mars 2000 |
Antisense therapy interferes with the expression of disease-causing proteins, thus offering a direct and selective intervention in the disease process. Besides the well known oligonucleotides ( |
955,00 €
|
| |
| |
Bridging the Pharmaceutical Earnings gap: Key Strategies in the race for growth 173 pages | Mars 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years. Where once near unrestricted revenue expansion existed, external pressures now act in unison |
955,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval 113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs 119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike. A great need exists for ph |
795,00 €
|
| |
| |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century 189 pages | Octobre 2000 |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century introduces and analyzes the five key enabling technologies and bioinformatics, which are currently driving pharmaceutical dru |
955,00 €
|
| |
| |
Pfizer's Recent Takeover 15 pages | Juillet 2002 |
On 15th July 2002, Pfizer announced the acquisition of Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.
|
300,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets 214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals. Mar |
795,00 €
|
| |
| |
The Pharmaceutical Mergers and Acquisitions Outlook 2001 128 pages | Octobre 2001 |
Pharmaceutical companies have recently undertaken extensive M&A activity to either build critical mass, create organic growth or through strategic alliances to build virtual mass. The Pharmaceu |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Indevus Pharmaceuticals: Premium Company Profile |
|
|
Introduction
Indevus Pharmaceuticals is a biopharmaceutical company focused on obtaining product candidates and product from other pharmaceutical and biotechnology companies through collaboration, in licensing and acquisitions. The company's acquisition of Valera Pharmaceuticals in April 2007 has expanded its product portfolio, establishing it as an emerging leader in the areas of urology and men's health.
Scope
Contains corporate strategy, value chain presence and SWOT AnalysisProvides detailed business description, segment analysis, 5-year financial trends, key products and key competitorsIncludes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Indevus Pharmaceuticals is a biopharmaceutical company engaged in the acquisition, development and commercialization of products to treat urological, gynecological and men's health conditions.
The company's marketed products are: Sanctura for the treatment of overactive bladder; Delatestryl for treating hypogonadism in men; Supprelin-LA for the treatment of central precocious puberty; and Vantas indicated in hormone suppression therapy for advanced prostate cancer.
Indevus Pharmaceuticals derives its revenues from contract and license fees and product revenues which include revenues from sales of products, commissions and royalties. The company obtains products and product candidates through acquisitions and licensing agreements with other pharmaceutical and biotechnology companies.
Reasons to Purchase
Access all the important information and analysis on the company in a single reportUnderstand company's strengths, weaknesses, opportunities and threats along with business strategy and value chainGain access to company's adjusted five year financial data along with key ratios and market capitalization
|
|
TABLE OF CONTENTS Overview 1 Catalyst 1 Summary 1 Company Structure 7 Company Overview and Key Facts 7 Business Description 8 History 9 Locations and Subsidiaries 13 Company Financials 14 Stock Market Performance 14 P&L 16 Balance Sheet 19 Cash Flow 19 Business Segment Performance 20 Products & Services 22 Marketed Products 22 Pipeline Products 24 AC Forecast Product Sales 27 Competitors and Strategic Business Relationships 30 Key Competitors 30 Key Suppliers 31 Key Clients 32 Shareholding Structure 34 Strategy 35 Company View 35 Corporate Strategy 37 SWOT Analysis 39 Overview 39 Strengths 40 Weaknesses 41 Opportunities 42 Threats 44 Value Chain Analysis 45 Overview 45 Discovery and Product Development 45 Manufacturing 46 Sales 46 Scorecard 47 Overview 47 Scorecard Analysis 48 Key Employees 49 List of Key Employees 49 Key Employee Biographies 50 Financial and Operational Overview 55 Financial and Operational Overview 55 APPENDIX 58 Ask the analyst 58 Datamonitor consulting 58 Disclaimer 58
TABLE OF FIGURES Figure 1: Indevus- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 17 Figure 2: Indevus- Key Strategic Revenues, 2002-2006 ($ Mn) 21 Figure 3: Indevus- Key Strategic Revenues, 2006-2010 ($ Mn) 29
TABLE OF TABLES Table 1: Indevus- Key Facts 7 Table 2: Indevus– Locations and Subsidiaries 13 Table 3: Indevus - Year-End Share Price and Market Capitalization, 2002-2006 ($) 14 Table 4: Indevus- Key Events Impacting Share Price Performance 15 Table 5: Indevus- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 16 Table 6: Indevus- Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 18 Table 7: Indevus – Balance Sheet, 2002-2006 ($ Mn) 19 Table 8: Indevus - Cash Flow, 2002-2006 ($ Mn) 19 Table 9: Indevus- Revenue Breakdown, 2002-2006 ($ Mn) 20 Table 10: Indevus- Marketed Products 22 Table 11: Indevus- In-house Pipeline Products 24 Table 12: Indevus- Collaboration Products 26 Table 13: Indevus- Forecast Sales, 2006-2010 ($ Mn) 27 Table 14: Indevus- Key Competitors 31 Table 15: Indevus- Key Suppliers 32 Table 16: Indevus- Key Clients 33 Table 17: Indevus- Key Shareholders 34 Table 18: Indevus- SWOT Analysis Summary 39 Table 19: Indevus- Value Chain Analysis 45 Table 20: Indevus- Scorecard 47 Table 21: Indevus- Key Employees 49 Table 22: Indevus – Financial and Operational Overview 56
|
|
|
PPLSEN
|
|
|
|
|